title: Effectiveness of relative low-dose interferon treatment for patients with chronic hepatitis C.
abstract: To demonstrate effectiveness by relative low-dose of interferon treatment for patients with chronic hepatitis C, we investigated the histological activity index (HAI) score of liver tissue, hepatitis C virus (HCV) genotype by polymerase chain reaction (PCR) with type-specific primers, HCV RNA levels by competitive PCR, serum aminotransferase, sex, age, history of blood transfusion and history of hepatitis in patients with chronic hepatitis C prior to treatment. Twenty-two patients were treated with human lymphoblastoid interferon (3 MU daily, 2 weeks, 3 MU thrice a week, 6 weeks, 1.5 MU thrice a week, 16 weeks) for 24 weeks, of whom 10 (45.5%) were responders within a 6 month follow-up. HAI score before treatment was significantly lower in responders than in a combined group of relapse patients and nonresponders (7.5 +/- 3.4 vs. 12.0 +/- 3.1, p < 0.01). The prevalence of responders in patients with genotypes III and IV was significantly higher than in those with genotype II (85.7% vs. 21.4%, p < 0.05). HCV RNA level (logarithmic transformed copy per 50 microliter of serum) was significantly lower in responders than in a combined group of relapse patients and nonresponders (4.8 +/- 1.2 vs. 5.7 +/- 0.8, p < 0.05). In case of other pretreatment factors, there were no significant differences between responders and a combined group relapse patients and nonresponders. Thus severe histological changes in the liver, HCV genotype II and high HCV RNA levels are markers of unfavorable effects of interferon treatment for patients with chronic hepatitis C.
authors.affiliation: Department of General Medicine, Kyushu University Hospital 71, Fukuoka.
authors.forename: J
authors.initials: J
authors.lastname: Hayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kishihara
authors.forename: Y
authors.initials: Y
authors.lastname: Tani
authors.forename: K
authors.initials: K
authors.lastname: Yamaji
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.forename: H
authors.initials: H
authors.lastname: Ikematsu
authors.forename: S
authors.initials: S
authors.lastname: Kashiwagi
mesh_terms: D000328:Adult; D001483:Base Sequence; D002908:Chronic Disease; D005260:Female; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha